Trending Topic

22 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This systematic review and meta-analysis investigate the efficacy of teprotumumab, a novel monoclonal antibody, in reducing proptosis for patients with long-duration thyroid eye disease (TED). While teprotumumab has shown promise in treating active TED, its effectiveness in chronic cases remained less certain. By synthesizing data from nine individual studies, this meta-analysis aimed to quantify the […]

< 1 min

An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England

Shraddha Chaugule, Nick Oliver, Brigitte Klinkenbijl, Claudia Graham
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Sep 11th 2017 European Endocrinology, 2017;13(2):81–85 DOI: https://doi.org/10.17925/EE.2017.13.02.81
Select a Section…
1

Abstract

Overview

Objective: To assess the economic impact of providing real time continuous glucose monitoring (CGM) for people with type 1
diabetes (T1D) and impaired awareness of hypoglycaemia (IAH) within North West (NW) London clinical commissioning groups
(CCGs). Methods: The eligible population for CGM and inputs for the economic budget impact model developed were derived from
published data. The model includes cost of CGM; cost savings associated with lower hypoglycaemia related hospital admissions, accidents
and emergency visits; self-monitoring of blood glucose (SMBG) strip usage; and glycated haemoglobin (HbA1c) reduction-related avoided
complications and insulin pump use. Results: The cost of CGM for T1D-IAH (n=3,036) in the first year is £10,770,671 and in the fourth year is
£11,329,095. The combined cost off-sets related to reduced hypoglycaemia admissions, SMBG strip usage and complications are £8,116,912
and £8,741,026 in years one and four, respectively. The net budget impact within the NW London CCGs is £2,653,760; £2,588,068 in years one
and four respectively. Conclusions: Introduction of CGM for T1D-IAH patients will have a minimal budget impact on NW London CCGs, driven
by cost of CGM and offsets from lower hypoglycaemia-related costs, reduced SMBG strip usage, avoided HbA1c-related complications and
lower insulin pump use.

Keywords

Continuous glucose monitoring, economics,
type 1 diabetes, clinical commissioning group

2

Article Information

Disclosure

Shraddha Chaugule is an employee
of Dexcom, Inc. Brigitte Klinkenbijl is an employee
of Dexcom, Inc. and owns stock in the company.
Claudia Graham is an employee of Dexcom, Inc.
and owns stock in the company. Nick Oliver has
nothing to declare in relation to this article.

Correspondence

Brigitte Klinkenbijl, International
Access, Dexcom Operating Limited, Tanfield, Edinburgh,
EH3 5DA, Scotland, UK. E: bklinkenbijl@dexcom.com

Support

The publication of this article was
supported by Dexcom, Inc. The views and opinions
expressed are those of the authors and do not
necessarily reflect those of Dexcom, Inc.

Access

This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.

Received

2017-07-11T00:00:00

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup